Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 3:14:1172851.
doi: 10.3389/fimmu.2023.1172851. eCollection 2023.

Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination

Nicole L Messina  1   2 , Mariana G Sperotto  3   4 , Marco A M Puga  3   4 , Patricia V da Silva  3   4 , Roberto D de Oliveira  5   6 , Cecilia L Moore  7 , Laure F Pittet  1   2   8 , Tenaya Jamieson  1 , Margareth Dalcolmo  9   10 , Glauce Dos Santos  11 , Bruno Jardim  12 , Marcus V G Lacerda  12 , Nigel Curtis  1   2   8 , Julio Croda  3   4   13
Affiliations
Randomized Controlled Trial

Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination

Nicole L Messina et al. Front Immunol. .

Abstract

Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.

Keywords: BCG; COVID-19; ChAdOx1-S; CoronaVac; antibody; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Participant flow chart. Participants in the BRACE COVID-19-Specfic vaccine (BCOS) sub-study were a subset of participants from the BRACE trial. BRACE trial participants in Brazil who received (or were due to receive) two doses of COVID-19-specific vaccines prior to August 9th 2021 and provided at least 1 BCOS-post-vaccination serum sample were eligible for inclusion. Participants were randomised to BCG or placebo vaccination in the BRACE trial a mean of 80 (standard deviation 41 days) prior to their first COVID-19 vaccination. ‡266 participants were included for dose 1 and dose 2 of ChAdOx1-S.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gordon C, Porteous D, Unsworth J. COVID-19 vaccines and vaccine administration. Br J Nurs. (2021) 30(6):344–9. doi: 10.12968/bjon.2021.30.6.344 - DOI - PubMed
    1. Claus J, Ten Doesschate T, Gumbs C, van Werkhoven CH, van der Vaart TW, Janssen AB, et al. . BCG Vaccination of health care workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomized placebo-controlled trial. mBio (2023) 14 (2):e0035623. doi: 10.1128/mbio.00356-23 - DOI - PMC - PubMed
    1. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. . T Cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med (2021) 27(2):270–8. doi: 10.1038/s41591-020-01194-5 - DOI - PubMed
    1. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. (2021) 396(10267):1979–93. doi: 10.1016/S0140-6736(20)32466-1 - DOI - PMC - PubMed
    1. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. . COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. (2020) 586(7830):594–9. doi: 10.1038/s41586-020-2814-7 - DOI - PubMed

Publication types